NORTHRIDGE, Calif. & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--Avita Medical Ltd. (ASX:AVH) (OTCQX:AVMXY), the regenerative medicine company, sponsored the inaugural Skin Regeneration Symposium held in Rome, Italy, 23-24 March 2012. The two day event provided a unique opportunity for expert users of ReCell® Spray-On Skin® to present their clinical research and experience in skin regeneration to their peers from around the world and Avita senior leadership. On 23 March 2012 a multi-disciplinary group of 24 invited ReCell experts from across the globe (Australia, China, France, Germany, Italy, Jordan, the United Kingdom and the United States) met together with Company leaders to advise on clinical best practices, clinical trials and product enhancement.
The open session on 24 March was attended by over 120 clinicians and physicians from 13 countries throughout Europe and the Middle East. Three panel discussions covered application of ReCell in the areas of Burn treatment, Plastic and Aesthetic applications (including the treatment of scar and vitiligo, and facial rejuvenation) and Hard-to-Heal wounds (including treatment of venous and diabetic foot ulcers and other chronic/challenging wounds). Panels were chaired by Dr Rajiv Sood (USA), Dr Jeremy Rawlins (UK) and Dr Fiona Woods (Australia), respectively. Each panel consisted of 5-6 prominent physicians who have integrated ReCell into their practise. The expert panels provided ReCell information and training to a large and influential network of surgeons and clinicians seeking the best therapies for treating wounds and skin defects.
An introductory presentation on the history and development of ReCell was delivered by Dr Wood (Australia), with the keynote lecture given by Professor Wei Li of the University of Southern California’s Keck School of Medicine describing the physiologic and biomolecular basis for the action of ReCell.
Dr William Dolphin, CEO of Avita Medical, said “Regenerative medicine is fundamentally changing the way we think about the treatment of a wide range of diseases, injuries and tissue defects. ReCell, as one of the first regenerative therapeutic technologies available, provides a new and tremendously powerful tool for surgeons and is markedly resetting their expectation for patient outcomes.”
The symposium led to a vibrant exchange of information, with strong implications for the advancement of the use of ReCell across the Middle East and Europe.
About Avita Medical Ltd.
Avita Medical (www.avitamedical.com) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. The company’s lead product, ReCell® Spray-On Skin®, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is not available for sale in the United States; in the U.S. ReCell is an investigational device limited to investigational use.